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In 1987, Ochiai et al., reported the immunosuppressive qualities of a new 
immunosuppressive agent, FK 506, isolated from the fermentation broth 
of a soil fungus, Streptomyces tsukubaensis. Extensive in vitro studies, 
demonstrated the effectiveness of FK 506 in suppressing mixed lympho-
cyte cultures, apparently by inhibiting IL-2 synthesis following alloactiva-
tion (Kino et al., 1987). The receptor for FK 506 has been identified, and 
has been characterized as a peptidyl-proly cis-trans isomerase (Harding et 
ai., 1989). 
The background for the clinical development of FK 506 was based on 
anum ber of animal models which have shown a marked ability of the drug 
to prevent rejection following various types of organ transplants (Starzl et 
ai., 1987; Todo et ai., 1988; Murase et al., 1990a,b), as well as to prevent the 
development of graft-versus-host disease (GVHD) following bone marrow 
transplantation (Markus et al., 1991a). More interestingly, FK 506 
possesses the ability to reverse ongoing rejection in animal models, a~well 
as established GVHD after bone marrow transplantation (Markus et at., 
1991 b). These properties continue to be evident during clinical testing of 
FK 506 (Starzl et al., 1989). 
This chapter will attempt to summarize the results of all human 
transplantation models in which FK 506 has been utilized as either 
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'rescue' therapy and/or 'primary' therapy, including liver (Starzl et al., 
1989; Fung et al., 1990; Todo et al., 1990), kidney (Starzl et al., 1990; Todo 
et al., 1990; Shapiro et aI., 1991), heart (Armitage et al., 1991) and bone 
marrow transplantation (Fung et al., 1990), at the University of Pitts-
burgh. 
Methods 
Study design 
The triats in liver, kidney, heart and bone marrow transplantation were 
conducted at the University of Pittsburgh, Presbyterian University Hosp-
ital, Children's Hospital of Pittsburgh and the Veterans Administration 
Medical Center, with the approval of the respective Institutional Review 
Bo~rdsK Informed consent was obtained from patients or their appointed 
guardians. 
Patient profiles 
In the liver study, patients were treated with FK 506 as part of three 
studies, one being the rescue study, in which 57 patients were entered for 
the diagnosis of acute rejection, while 116 patients were converted from 
cyclosporin A (CsA) to FK 506 for chronic rejection. In the primary liver 
transplant group, 110 patients were treated with FK 506 and low-dose 
steroids, as the baseline immunosuppression following liver transplanta-
tion. A subsequent study involved a total of 81 patients, prospectively 
randomized to either FK 506 or CsA as the baseline immunosuppression 
following liver transplantation. 
In the kidney study, patients were treated with FK 506 as part of two 
studies, one being the rescue study, in which 21 patients were entered for 
the diagnosis of rejection. In the primary kidney transplant group, 202 
patients were treated with FK 506 and low-dose steroids, as the baseline 
immunosuppression following kidney transplantation. A randomized trial 
comparing FK 506 and CsA primary kidney transplantation included 26 
patients in both arms. 
In the heart study, patients were also divided into two groups. In the 
first group, 30 patients were treated with FK 506 for primary immunosup-
pression, while in the second group, ten patients were converted to FK 506 
because of persistent rejection. 
In the bone marrow study, patients were entered as part of a rescue 
study, in which 14 patients were treated with FK 506 for evidence of 
persistent manifestations of graft-versus-host disease, unresponsive to 
conventional treatment protocols. 
, ' 
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Diagnostic evaluations 
For patients who were experiencing organ dysfunction, the final categori-
zation of dysfunction was based upon clinical, biochemical and/or histo-
pathological findings. For all patients, either as primary or as rescue 
therapy, cause(s) or organ dysfunction were carefully sought, the workup 
being customized to the organ or tissue transplanted. Ultrasonic determi-
nation of vessel patency and radiographical evaluation of the biliary or 
urinary system were used to rule out a technical or mechanical defect. 
Angiography was performed when indicated. Appropriate viral cultures 
and stains were used to detect viral infections. 
Protocol biopsies were utilized in the evaluation of efficacy of FK 506 
therapy. All biopsies were blinded and interpreted by a single experienced 
transplant pathologist (A.JD.). Biopsy specimens were fixed in neutral 
buffered formalin and stained routinely with haematoxylin and eosin, 
trichrome and reticulin stains. The criteria used for pathological diagnosis 
have been defined in previous reports (Billingham et al., 1979; Demetris et 
al., 1990). 
Timing and details of therapy 
Initiation of treatment with FK 506 was done in the hospital and was 
given initially as a parenteral dose, followed by conversion to an oral dose. 
The initial parenteral dose of FK 506 was 0.075-0.15 mgjkg, given 
intravenously. This was continued until the patient was able to ingest the 
oral form of FK 506. Generally, oral dosages of FK 506 were given at 
0.30 mgjkg/day, in two divided doses. Dose adjustments of FK 506 were 
based upon monitoring of serum trough levels by enzyme linked immuno-
sorbant assay (ELISA) (Tamura et at., 1987) to achieve a 12-h trough level 
between 1.0-2.0 ng/ml, and also by adjustment according to clinical or 
biochemical parameters. J 
Evaluation of response 
Periodic determinations of liver and kidney functions, including total 
bilirubin (TBIL), serum glutamic transaminases, SGOT and SGPT, 
alkaline phosphatase, blood urea nitrogen (BUN) and serum creatinine 
were performed. All values are expressed as the value ± 1 s.d. Protocol 
biopsies were obtained after initiation of FK 506 therapy. 
Liver transplantation 
Rescue therapy 
In this population of 173 patients, of whom many were critically ill at the 
time of FK 506 conversion, there were 14 deaths (8.1%). The causes of 
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death were numerous, but the incidence of mortality was directly corre-
lated with the medical condition of the patient at the time or FK 506 
conversion. Sepsis was the cause of death in four patients. Three patients 
died of haemorrhagic complications. Three patients died of metastatic 
carcinoma following transplantation. In two patients, retransplantation 
was not considered an option for the failing liver allograft. One patient was 
started on FK 506 with pathological findings oflate chronic rejection, and 
died of technical causes during an attempted retransplantation. In one 
death no cause of death could be determined. This patient died at home 
and had been off FK 506 for 4 months when she died. She had renal failure 
and was on dialysis prior to and after discontinuation of FK 506 therapy. 
The biochemical response of the liver allografts to FK 506 was 
analysed by classifying patients either into acute or chronic rejection, 
dependent upon the principal histopathological findings. For the 57 
patients who were treated for acute rejection, documented on liver biopsy 
or as judged by biochemical and clinical parameters, the TBIL, SGOT, 
and SGPT values prior to FK 506 were: 4.68 ± 5.91 mg/dl,240 ± 431 iu/I, 
and 292 :±f~PUP iu/I, respectively, These values fell, by the sixth month to: 
0.76 ± 1.41 mg/dl, 98 ± 163 iu/l, and 90 ± 128 iu/l, respectively. 
Patients with an entrance diagnosis of chronic rejection also had a 
beneficial response to FK 506. For the 116 patients treated for this specific 
indication, the total bilirubin fell to normal values (pre-FK 506, 5.07 ± 
8.16 mg/dl; 6 months, 0.99 ± 1.47 mg/dl) while the average transaminase 
values were still slightly elevated above normal values (pre-FK 506, 
SGOT/SGPT, 200 ± 175 iu/I/275 ± 223 iu/l; 6 months, SGOT/SGPT, 
44 ± 72 iU/l/101 ± 68 iujl). 
A clinicopathological study of the results of conversion of liver 
allografts from CsA to FK 506 immunosuppression revealed that the 
biochemical improvement seen above was correlated with histopathologi-
cal improvement (Demetris et al., 1991). With both acute and chronic 
rejection, the biochemical improvement occurred earlier and in greater 
proportion than the pathological findings. Those patients with acute 
rejection fared better than those with chronic rejection, with a higher 
response rate. In those patients with chronic rejection, the liver function 
studies and the degree of bile ductular injury was significantly worse 
among those who failed than among those patients who responded. 
Primary therapy 
Of the original 110 primary liver transplant patients in the series, a total of 
99 E9M~~F were alive at 12 months. These results were statistically better 
than those of the 325 CsA-treated control group, which had a I-year 
patient survival of onl¥ 77%. The corresponding graft survival was also 
statistically better, with 83% of the FK 506 grafts surviving at 1 year, 
compared with 68% for the CsA group. The rate of retransplantation was 
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only 6%, over one-half less than the 15% retransplant rate seen with the 
CsA control group. The 60-day mortality figure for FK 506-treated 
patients (6. T~/~F was statistically less than that of CsA E1SKR°~FK 
During the follow-up period. RM/~ of all recipients were taken off 
steroids and were maintained on single drug immunosuppression with FK 
506. Yet ROKU~~ of all patients were rejection free during the entire period of 
study. The majority of rejection episodes were mild and easily controlled 
with a single dose of bolus steroids (either methylprednisolone or hydro-
cortisone). Only 1TKU~~ of the rejection episodes required further steroid 
treatment in the form of a steroid taper or additional steroid boluses. In 
addition, only 11KO~D~ of the patients required anti-human CD3 (OKT3). 
The incidence of serious infections, in spite of the potency of F)<. 506, 
does not appear to be alarming. The incidence of serious infectiO'ns was 
about RM/~ less than that seen with a historical group of patients given 
esA. Of note, is that the incidence of cytomegalovirus infections did not 
appear to be increased, when compared to patients on CsA. 
Prospective randomized study 
Based upon the encouraging results of the preliminary FK 506 experience, 
a study was started. comparing the use of FK 506 and CsA, along with 
steroids, in a prospective, randomized fashion, in patients undergoing 
primary liver transplantation. Eighty-one liver transplant recipients were 
randomized to either FK 506 (41 patients) or CsA (40 patients), following 
completion of the liver transplant. A single bolus of 1 g methylpredniso-
lone followed by a daily dose of 20 mg methylprednisolone was the 
baseline steroid therapy for both groups of patients. Biochemical and 
histopathological parameters were monitored in order to determine the 
effectiveness of either therapy in preventing rejection. Rejection episodes 
were treated with a single bolus of 1 g methylprednisolone. If this 
treatment failed to reverse the rejection episode, a total of 50 mg 0 K T3 
was administered. Those CsA patients who failed to respond to therapy 
were converted to FK 506, in an attempt to rescue the dysfunctional graft. 
With the ability to rescue CsA randomized dysfunctional grafts with FK 
506, the patient and graft survival were essentially the same. 
The median follow-up for both the CsA and FK 506 groups was 345 
days (range 256-446 days). The 6-month-patient survival rate was 95% for 
the FK 506-treated group, while the corresponding value for the CsA-
treated group was U9~~K The corresponding graft survival was 93% for the 
FK 506-treated group, while the corresponding value for CsA-treated 
group was 81 %. The 12-month-graft survival rate was 90% for FK 506, 
and 70°0 for CsA. Two patients in the FK 506-treated group and seven 
patients in the CsA-treated groups were retransplanted. The mortality 
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associated with retransplantation was 50% in both groups. The total 
percentage of patients in the FK 506 group who were rejection-free during 
the entire length of follow-up was 53.7%, while that for CsA was 13.3%. 
The mean days to the first rejection was 21.5 days for the FK 506-treated 
group, and 9.9 days for the CsA-treated group. OKT3 for treatment of the 
original allograft was used in 30% of CsA-treated patients, compared with 
OM~~ of FK 506-treated patients. Steroid boluses averaged 0.99 times in the 
CsA-treated group, while this figure was 0.50 times in the FK 506-treated 
group. TOKS~/~ of the CsA-treated patients were converted to FK 506, an 
average of 20 days after liver transplantation. The reasons for conversion 
were: persistent ischemic injury (5), patient dropout (1), Rh incompatibili-
ty with haemolysis (1), and steroid resistant or OKT3-resistant rejections 
(21). 
Renal function in both groups of patients was assessed by the 
requirement for haemodialysis and the serum creatinine at monthly 
determinations. Haemodialysis was initiated in six CsA patients while still 
on CsA, while three other CsA patients required haemodialysis during the 
period of conversion to FK 506. In the FK 506-randomized group, four 
patients were placed on haemodialysis during the post-transplant period. 
The comparative incidence for haemodialysis requirement between the 
FK 506 and CsA groups was 10% and O1KS~~I respectively. Long-term 
haemodialysis (after 3 months post-transplant) was required by one 
patient in each group. 
The incidence of opportunistic infections was essentially the same for 
both groups. Patients who were randomized to CsA had a 22.5% incidence 
of cytomegalovirus (CMV) infections. This compared to a 22.0% incidence 
for patients on FK 506. In the 13 CsA patients who were not switched to 
FK 506, the incidence of CMV was 23% (3/13), and only one of the three 
patients received OKT3. In FK 506 patients, three of a total of nine cases 
of CMV occurred in patients who had previously received OKT3. 
The severity of hypertension was assessed by the need for antihyper-
tensive medications following transplantation. The incidence of hyperten-
sion in the overall CsA-randomized group was 52.9% versus 26.9% for the 
FK 506-treated group (P < 0.01), at 3 months post-transplant. This figure 
did not change appreciably over the follow-up period; at the 12-month-
follow-up period, the corresponding hypertensive incidence was 48% for 
CsA and 33.3% for FK 506. The incidence of hypertension in the 14 
patients, who were on CsA at the 3 month post-transplant period was 
S4KO~~K The 12-month figure was 72.7% for those patients still on CsA, 
while the conversion group had an incidence similar to those given FK 506 
from the start EPSK4~/~FK 
The need for insulin therapy was evaluated by determining those 
patients who required il!sulin at the 3-month period following transplanta-
tion. There were no statistically significant differences between the two 
\" 
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groups of patients. 1T~~ of the patents in the FK 506 group required 
insulin at 3 months post-transplant. For the .esA group, 17.5% of the 
patients required insulin at the same time point. 
Both FK 506 and esA administration have been associated with side-
effects, many of which are similar. The percentages and severity of patients 
experiencing treatment-related adverse reactions were recorded. This 
included evidence of neurotoxicity: trembling, paresthesias, insomnia, 
irritability, hyperkinetic behaviour, dysarthria, seizures, and coma. The 
incidence of side-effects was essentially the same in both groups. 
The results of the current randomized study compare favourably with 
previously reported results using FK 506, and therefore do not appear to 
represent a bias in the performance of the study. It is important that the 
results of the current ongoing randomized trial are comparable to those 
results obtained in the historical series. The current results of patient and 
graft survival are as good, if not better, than those figures obtained in the 
past. One would expect that both graft and patient survival would be 
better in the randomized trial since high-risk patients are removed from 
randomization. The randomized FK 506 liver patients were compared to 
the survival curves of 271 non-randomized FK 506 recipients and 813 esA 
recipients during the period of time corresponding to the utilization of 
Viaspan (Dupont). The I-year patient survival for the high-risk FK 506 
liver recipients not entered in the randomized trial approaches UO/~I while 
graft survival is TS~~K This compares to our historic esA patient and graft 
survival of 77% and 68%, respectively. The improvement of the current 
randomized esA group over the historic group may, in part, be, related to 
the ability to convert patients on esA to FK 506. 
Kidney transplantation 
Rescue therapy 
A total of 21 patients were converted from esA-based immunosuppression 
to FK 506-based immunosuppression for persistent kidney rejection. One 
death was encountered. Of the 21 patients, ten were classified into late 
rejection episodes (> 60 days), while 11 were treated early in the post-
transplant course ( < 60 days). Seven of the 11 early rescues were success-
ful, in contrast to only four of ten late rescues. Most of the failures of FK 
506-rescue therapy in this group of patients were in patients who had 
chronic glomerulosclerosis and chronic rejection on biopsy, prior to FK 
506 rescue. In those patients with acute cellular rejection, the results were 
better. The serum creatinine at the time of conversion, was also correlated 
with the success of therapy. Four of five EUMD1~F patients with a serum 
creatinine < 3.0 mg/dl have good renal function, while only seven of 16 
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E44~~F patients with a pre-conversion serum creatinine > 3.0 mg/dl have a 
functioning kidney. The overall serum creatinine prior to FK 506 conver-
sion in the 11 successful switches was 3.70 ± 2.15 mg/dl, excluding the 
serum creatinine values of four patients who were on dialysis at the time of 
FK 506 conversion. The average creatinine after FK 506 switch was 
2.84 ± 1.40 mg/dl, with all 11 grafts functioning. 
Primary therapy 
On March 27, 1989, a trial utilizing FK 506 and low-dose steroids was 
introduced at the University of Pittsburgh. A total of 411 kidney trans-
plants have been performed during the period between 3/27/89 and 1/31/ 
91. Twenty-nine kidneys were transplanted into patients who were reci-
pients of other organ transplants. The results of these patients were limited 
by other factors such as patient survival and graft function of other organs, 
primarily that of the liver, and were excluded from further analysis. A 
study of the remaining 382 kidney transplant patients included 202 
patients given FK 506 and low-dose steroids and 180 patients given CsA, 
low-dose steroids and azathioprine. 
The average age of the recipients was 39 years; 11KP~~ of recipients 
were over 60-years old and 8.4% were in the paediatric age range. 
Approximately two-thirds of the patients in both groups were receiving 
their first kidney transplant. Fifteen per cent of patients were considered 
high antibody status (panel reactive antibodies (PRA) > 40%). placing 
them in a high-risk category for kidney transplantation. A slightly higher 
percentage of patients with living related transplants were given CsA (I 4~;D; 
CsA versus 5% FK 506). while paediatric donors accounted for a higher 
percentage of the organs used in the FK 506 group (22% FK 506 versus 
1R~~ CsA). The mean follow-up was 11.3 ± 7.5 months. The overall patient 
survival at I year was 94.3% for the CsA group and 90.6% for the FK 506 
group. The causes of death were similar between both groups, with cardiac 
causes accounting for PM~~ of deaths, sepsis for OS/~ of deaths and 
gastrointestinal complications for OO~1o of deaths. 
For those patients receiving their first kidney transplant, the patient 
survival was essentially the same (92.8% CsA versus 92.7% FK 506). The 
graft survival at 1 year for these patients was 81.5% for the CsA group and 
75.3% for FK 506. For the low immunological risk patients (PRA < 4M~~FI 
the patient survival was 94.1 ~~ for CsA and 91.1 % for FK 506, while the 
corresponding graft survival for the CsA was 81 % versus TS/~ for FK 506. 
Prospective randomized study 
A randomized trial of FK 506 with low-dose steroids versus CsA with low-
dose steroids was initiated in April, 1990. At this time, patients who were 
""~="""~ • ~ I~~ "~"DDf}fD" "r~Df:t"D-~D" ~ ~"D~~" K~ ~ ~I-I~ , , 
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considered as low-risk candidates for kidney transplantation, i.e. receiving 
their first kidney transplant without significant known medical problems, 
and with low PRA, were randomized to either FK 506 or esA with low-
dose steroids. Patients who did not fulfill these criteria were considered 
high-risk patients and received FK 506 and low-dose steroids as part of a 
non-randomized protocol. When the results of patient and graft survival 
were examined, breaking down the randomized from the non-randomized 
patients, the effect of the non-randomized group on the FK 506 statistics 
could be seen. The patient and graft survival of the randomized patients 
were essentially the same (see Figs 7.1 and 7.2). The 1 year patient survival 
in the randomized esA group was 92% and 9S~;D; for the FK 506 group. 
The corresponding graft survival was 79% and 81 %. By shifting the high-
risk patients into the FK 506 non-randomized trial, the overall patient and 
graft survival were lower in the FK 506 group. The I-year patient and graft 
survival for the FK 506 non-randomized group was 90% while that for the 
esA was 9R~oD More importantly, because of higher numbers of retrans-
plant cases in the FK 506 group (32% for FK 506 versus 21% for esA), the 
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overall graft survival were somewhat less in the FK S06 group ET4~~F when 
compared to the CsA group EUO~/~FK The rates of rejection in the overall 
groups were similar, S7% in the FK S06 group and 54% in the CsA group. 
The randomized trial was designed to evaluate not only patient and 
graft survival, but also to assess the effect of either FK S06 or CsA on other 
parameters such as the incidence of hypertension, infection, requirement 
for augmented immunosuppression, rates of rejection, and steroid require-
ments. Fifty-two patients were enrolled in the study, 26 randomized to 
both arms. The incidence of biopsy documented rejection was TP/~ in the 
CsA group and 46% in the FK 506 group (P < O.OS). Moreover, the 
requirement for OKT3 was 50°1" in the CsA group and 19% for the FK 506 
group (P < 0.03). Thirty-five per cent of the esA group required conver-
sion to FK S06, while 4% ofthe FK 506 were considered treatment failures 
and required addition of azathioprine to control rejection. The rates of 
CMVinfection were essentially the same, IS% for esA and 12% for FK 
506. The overall renal function was similar in both groups, with a mean 
serum creatinine of 1.9 mg/dl, and a mean blood urea nitrogen of 28 mg/dl 
for CsA and 26 mg/dl for FK 506. While over one-third of FK 506 patients 
were off steroids at the time of analysis, no esA patient was steroid free 
(P < 0.01). While only 29% of patients on esA were given no antihyper-
tensive medications, over one-half (S2%) of patients on FK S06 were free of 
antihypertensive medications (P < O.OS). 
Heart transplantation 
Rescue therapy 
Ten patients were converted from esA to FK 506 between 3 and 50 
months post-transplant. The findings of persistent heart rejection defined 
by a > 2 + grading of the endomyocardial biopsy by the Billingham 
criteria (Billingham et al., 1979), included mononuclear cell infiltration, 
arteritis and in some instances, interstitial fibrosis. All patients had failed 
conventional immunotherapy, including at least two courses of antilym-
phocyte preparations, and two courses of augmented steroids during the 
preceding 6 months. The grading of endomyocardiaI biopsies, prior to 
conversion of FK 506, was 2.70 ± 0.48. Using the same criteria, the mean 
value of the follow-up biopsies after FK 506 was graded at 0.70 ± 0.67 
(P < 0.01). The mean prednisone dose prior to FK 506 conversion was 
14 mg/day, after FK 506 conversion this fell to 5.5 mg/day. One death 
occurred during the period of follow-up in a patient with disseminated 
aspergillosis. 
. ; 
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Primary therapy 
Thirty patients received FK 506 from the outset fctllowing heart transplan-
tation. Eight patients were on circulatory assist devices prior to heart 
transplantation. Follow-up ranged from 1 to 10 months. Four patients 
have died, with an actual patient and graft survival of 87%. One patient 
with known pulmonary hypertension died on the third post-transplant 
day from right heart failure. One patient, with pre-existing lung disease 
and bronchiectasis. died from pulmonary infection, while two other 
patients died of sudden deaths, without a known cause. The rejection-free 
rate within the first 90 days was SM/~K Only one patient required OKT3. 
Heart function was excellent in all patients. The average left ventricular 
rejection fraction, determined by gated nuclear scans or echocardiogra-
phy, was TM~~ (range RU-TR/D~FK 
Bone marrow transplantation 
Rescue therapy 
Fourteen patients with manifestations of chronic GVHD following bone 
marrow transplantation were placed on FK 506. All patients were on or 
had been on high doses of esA and steroids. Seven patients had an original 
diagnosis of chronic myelogenous leukaemia, three were given bone 
marrow transplants for acute lymphoblastic leukaemias, one had aplastic 
anaemia, one for Burkitt's lymphoma and two had acute myelogenous 
leukaemias. All grafts were taken from human leukocyte antigen (HLA) 
identical siblings. The most common sites of involvement are skin and 
liver, followed by lung, gastrointestinal and musculoskeletal. The most 
objective parameters to evaluate response to FK 506 have been those 'with 
liver and skin involvement. The mean time after bone marrow transplanta-
tion to the time of FK 506 therapy was 17.7 months, and the mean follow-
up was 5.8 months. 
Of the 11 patients with liver involvement, five were referred for 
consideration for liver transplantation. Two of these eventually required 
liver transplantation, but both died. One died from sepsis following liver 
transplantation, while the other patient failed to awaken after transplanta-
tion, having been in stage IV coma prior to transplantation. Two other 
patients died, one of unknown causes at home, and the other from 
respiratory failure from pre-existing severe bronchiolitis obliterans. The 
other six patients had a marked response to FK 506-rescue therapy. 
In the 11 patients with skin involvement, five have improved, while 
three with scleroderma like involvement have stable skin lesions. One of 
the patients dropped out of the study while two other patients died, one 
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from pulmonary aspergillosis and the other of unknown causes. 
Of the six patients with moderate to severe obliterative bronchiolitis, 
two patients died from worsening lung disease. The remaining four 
patients have stable or slightly improved pulmonary function. The remain-
ing organ system involvement of musculoskeletal and the gastrointestinal 
tract have not shown progression during FK 506 therapy. 
Limitations 
Adverse reactions requiring treatment or adjustment of FK doses can be 
catagorized into four primary areas. These are (i) alterations in kidney 
functions; (ii) alterations in glucose metabolism; (iii) neurotoxicity; and 
(iv) susceptibility to infection or malignancy. 
Alterations in kidney function are manifested by electrolyte abnorma-
lities and changes in glomerular filtration, as evidenced by changes in 
serum creatinine. Hyperkalaemia is seen in 35% of patients, following 
administration of FK 506. Treatment of hyperkalaemia is generally with 
potassium-binding resins and potassium-restricted diets. Addition of a 
synthetic mineralocorticoid, Florinef, relieves the hyperkalaemia, by in-
creasing potassium excretion by the kidney. Decrements in renal blood 
flow have been documented by nuclear medicine studies. The filtration 
fraction generally remains the same. Causes of altered renal function in 
transplant patients are multifactorial, and include: peri-operative hypo-
tension, use of nephrotoxic antibiotics and a degree of pre-existing renal 
dysfunction. The alteration in renal function seen in patients on FK 506 is 
similar to that seen in patients on CsA. These changes are responsive to 
reduction in doses of FK 506. The incidence of renal failure requiring 
chronic haemodialysis is of the order of 4~~I based on studies of liver 
transplant patients, although no patients have required maintenance 
haemodialysis following heart transplantation. The progression of chronic 
renal failure to dialysis-requiring renal failure is not known. 
Alterations in glucose metabolism are the result of changes in peri-
pheral sensitivity to insulin and/or changes in the response of the islet cells 
to hyperglycaemia. The incidence of new onset diabetes, i.e. those patients 
requiring insulin, is approximately 15% in FK 506 transplant patients. The 
incidence of new onset diabetes in other immunosuppressive regimens, 
incorporating CsA or azathioprine, is approximately OM~~K The long-term 
consequence of insulin requirement in transplant patients, towards the 
development of diabetic complications is not known. 
Rare but severe instances of neurotoxicity have been reported follow-
ing FK 506 administration. Expressive aphasia has been seen in four liver 
transplant patients, although this has not been seen in any other types of 
FK 506-treated individuals. New onset seizures have also been reported in 
liver transplant patient.s, especially during the peri-operative transplant 
" 
150 CHAPTER 7 
period. The susceptibility of such patients to changes in serum electrolytes 
has been previously reported. New onset seizures have not been reported 
in other patients treated with FK 506. 
Post-transplant lymphoproliferative disease (PTLD) is an abnorma-
lity of lymphocyte proliferation in a setting of an immunosuppressed 
patient. The spectrum of PTLD can range from a benign lymphoid 
proliferation such as a mononucleosis syndrome to a frankly malignant 
lymphoid tumour. PTLD has been associated with all types of immuno-
suppressive therapy. The incidence of PTLD in the cyclosporin era is 
generally estimated between 2 and 4%. The median time following 
transplantation to the development of PTLD is 6 months; the majority of 
these tumours occur within 12 months following transplantation. 
A total of 16 patients have developed de novo PTLD lesions while on 
FK 506 therapy. Seven of these patients died, although PTLD was 
associated with death in only five cases. The remaining nine patients had 
relatively mild forms of PTLD, three of these had a mononucleosis 
syndrome, and presented with sore throat and tonsillar enlargement. 
Treatment with lowering immunosuppression and intravenous acyclovir 
proved to cure all of them. In the remaining six patients, three required 
operative procedures (two small bowel resection, one liver resection) 
which were directly related to PTLD, while the other three were treated by 
a reduction of immunosuppression only. The incidence of de novo PTLD 
following initiation of FK 506 therapy is 1.4%. All of the cases of PTLD 
occurred within the first year following initiation of FK 506, with the 
median time from FK 506 therapy to onset of disease being 4 months. FK 
506 shows no evidence of any increase in the risk of developing or 
succumbing to PTLD, when compared to previously quoted figures on the 
incidence of PTLD, based on other immunosuppressive regimens. No 
patients treated with FK 506 for non-transplant indications have <tevel-
oped any malignancies. 
Cytomegalovirus infections are considered the most common oppor-
tunistic infection in the transplant patient. Several factors determine the 
severity and development of CMV infections. The seronegativity and use 
of intensive immunosuppression are considered major contributing fac-
tors. The incidence of CMV infections in the FK 506-treated transplant 
patients is 20%. This figure is similar to that seen in transplanted patients 
on CsA. No patients treated with FK 506 for non-transplant indications 
have developed CMV infections. 
Discussion 
Cyclosporin-based immunosuppression significantly enhanced both pa-
tient and graft survival in all solid organ transplants, when compared to 
the era of azthioprine and steroids (Starzl et aI., 1990). Its use in bone 
marrow transplantation has decreased the incidence and severity of 
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GVHD (Sullivan et aI., 1988). Nevertheless, most centres experience an 
unacceptably high complication rate related to ongoing GVHD or 
rejection. These immunologically related complications occur in over 70% 
of all cyclosporin-treated patients. In addition, the sequela of over-
immunosuppression in attempts to treat rejection or GVHD, such as the 
use of excessive steroids and antilymphocyte preparations, are fraught 
with a high incidence of infectious complications. It stands to reason that a 
baseline immunosuppressive agent which allows for less incidence of 
rejection or GVHD, and easier treatment, would decrease both graft and 
patient loss. From the results of our studies presented here, the use of FK 
506 in transplantation has these advantages. FK 506 appears to not only 
decrease the absolute incidence of rejection episodes, but makes the 
treatment of rejection simpler. 
The ability of a new immunosuppressive agent to be dose adjustable 
for treatment of acute rejection, chronic rejection or GVHD, would 
represent an important asset; this ability has only been ascribed to steroids 
in the past. FK 506 can be used in this manner. In fact, the first response to 
a developing rejection, is to increase the dose of baseline FK 506. In rescue 
therapy, the marked ability of FK 506 to reverse acute rejection in both 
kidney and heart rejection, and both acute and chronic rejection in liver 
transplantation, and with chronic GVHD in bone marrow transplantation 
has not been seen with any immunosuppressive agent in the past. While 
the mechanism by which FK 506 is able to do this, is not known, it would 
appear that it would entail mechanisms other than simply inhibition of IL-
2 synthesis. 
The limitations of FK 506 have been defined. In chronic rejection, the 
ability of an organ to reverse the stigmata of chronic inflammation 
appears to determine the effectiveness of FK 506 rescue therapy. With the 
development of obliterative arteriopathy, or the absence of epithelial 
structures, e.g. biliary structures or kidney tubules, the ability of FK 506 to 
reverse organ dysfunction is limited. On the other hand, acute cellular 
rejection appears to respond well to initiation or adjustment of FK 506 
therapy. 
Prospective, randomized trials comparing FK 506 therapy with 
cyclosporin-based immunosuppression are currently underway. The pre-
liminary results of the study being performed at the University of 
Pittsburgh in liver transplantation, are encouraging. Multicentre trials are 
also underway, and preliminary reports are also encouraging. A well 
defined endpoint, other than patient or graft loss, should be utilized, since 
the data presented here also suggests that a conversion to FK 506, will 
allow for allografts in danger of being lost to rejection, to be salvaged. 
Other randomized trials in kidney, heart and bone marrow transplan-
tation are also underway. The results of the randomized kidney transplant 
trial at the University of Pittsburgh has demonstrated a benefit of FK 506 
in several important secondary endpoints, e.g. incidence of hypertension, 
... 
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although the primary endpoints of patient and graft survival are similar. 
One other centre, in Japan, has had some early experience with FK 506 for 
primary kidney transplantation. Between July and September 1990, 37 
patients (32 living related and five cadaveric allografts) were enrolled in a 
study utilizing a fixed dose of 0.15 mg/kgjday intravenously followed by a 
fixed oral dose of 0.30 mg/kg/day. No attempts to adjust FK 506 doses to 
levels were made until an adverse event occurred. With follow-up of 5-8 
months, all patients were alive, and all grafts functioning. Twenty-five per 
cent of patients were converted to other immunosuppressive drugs be-
cause of adverse events. Rejection was noted in 32% of the patients 
although no patients required OKT3. Nephrotoxicity was seen in 30% of 
patients, and responded in 92% of patients to a decrease in FK 506 dose. 
Adverse reactions to the drug were proportional to high levels of FK 506. 
The toxicity profile of FK 506 is proportional to the efficacy of the 
drug. The major side-effects of the drug are similar to cyclosporin, with 
dose-related nephrotoxicity and neurotoxicity. Other known complica-
tions of immunosuppression, including diabetogenesis, infectious and 
malignant complications, are no greater with FK 506 than with other 
immunosuppressive therapies. As with any new agent, details regarding 
nuances of dose administration and adjustments, are continuing to be 
refined. In fact, it has been recently reported that FK 506 dosing must be 
adjusted to liver function and that attention to drug levels may be helpful 
in avoiding overdosing (Abu-Elmagd et aI., 1991; Starzl et aI., 1991). 
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